HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.

AuthorsAmbikalmajan M R Pillai, Furn F Russ Knapp Jr
JournalCurrent radiopharmaceuticals (Curr Radiopharm) Vol. 9 Issue 1 Pg. 6-7 ( 2016) ISSN: 1874-4729 [Electronic] United Arab Emirates
PMID26655262 (Publication Type: Editorial, Introductory Journal Article)
Chemical References
  • Antigens, Surface
  • Radioisotopes
  • Radiopharmaceuticals
  • Lutetium
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
Topics
  • Antigens, Surface (administration & dosage)
  • Glutamate Carboxypeptidase II (administration & dosage)
  • Humans
  • Lutetium (administration & dosage, therapeutic use)
  • Male
  • Prostatic Neoplasms (radiotherapy)
  • Radioisotopes (administration & dosage)
  • Radiopharmaceuticals (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: